Only one test predicts how a patient will respond to immune checkpoint inhibitor (ICI) therapies:
EpiSwitch (CiRT)
The first-of-its-kind blood test predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy.
EpiSwitch CiRT provides patient specific guidance to support informed decision-making regarding the treatment plan you create for your patient.
Watch CiRT Video Frequently Asked QuestionsBenefits of EpiSwitch CiRT
Now every patient can benefit from the world's first test to assess the probability of therapeutic success of checkpoint inhibitor therapy with high accuracy.
Understand your patient's likelihood of response to guide your decisions on beginning or continuing treatment with an ICI
Among patients experiencing an adverse reaction or toxicity, use the test to identify those who are likely to benefit from continued treatment
Improve overall patient response rate by accurately stratifying patients based on their likelihood of response
Fast and actionable prediction of a patient's personalized probability of response.
With a routine qPCR blood test, our comprehensive and validated approach delivers an easy-to-understand, confidential report that includes a prediction of individual patient response, with no need for a biopsy.
Patients with a positive EpiSwitch CiRT result can begin or continue their therapy confidently.
EpiSwitch® CiRT Report
Personalize your guidance for each patient
The test is intended to identify your patient's likelihood of response to an immune checkpoint inhibitor (ICI) therapy.
Individuals with a response level in the high probability range have a greater chance of benefiting from an ICI. Conversely, individuals with a response level in the low probability range have a reduced chance of benefiting from an ICI. These results should be considered along with other clinical features for interpretation by a licensed medical professional.
The EpiSwitch CiRT report includes indications for a healthcare professional to interpret a patient's likelihood of response to ICI therapy and formulate an effective management plan.
View Sample ReportEpiSwitch CiRT Response Profile
Your Response Level
The EpiSwitch Checkpoint Inhibitor Response Test (CiRT) result for this specimen is in the High Likelihood of Response range to an ICI therapy. Individuals in the group have a greater chance of benefiting from an ICI agent. This result should be considered along with other clinical features for interpretation by a licensed medical professional.
EpiSwitch CiRT is a validated test for predicting response to an ICI.
EpiSwitch CiRT delivers high sensitivity and specificity for predicting the beneficial use of an ICI. The blood test measures eight epigenetic markers to determine the most likely outcome of treatment.
0%
accuracy
0%
sensitivity
0%
specificity
0%
ppv
0%
npv
Download the Technical Overview to learn more about how EpiSwitch® CiRT can help guide treatment decisions for patients and their providers.
Download Technical OverviewAre you interested in becoming an EpiSwitch® CiRT registered healthcare provider?
Contact EpiSwitch CiRT Customer Service at 888-236-8896 (US) or 01865 504932 (UK) to open an account, request customized EpiSwitch® CiRT Requisition Forms branded for your practice, order EpiSwitch CiRT collection kits, or request further assistance relating to EpiSwitch CiRT. We look forward to speaking with you.
Download the Requisition Form and order your patient's test today.
Download the Requisition Form (US) Download the Requisition Form (UK)
